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Abstract
Background: Caesarean section (CS) is not recommended for PMTCT in Malawi HIV Guidelines, contrary to most
high-income countries where CS is indicated if viral suppression is sub-optimal pre-delivery. We describe patterns of
CS in HIV-infected and uninfected women in Malawi and explored if insight into the use of Elective CS (ECS) for
PMTCT could be obtained.
Methods: We used routinely collected data from individual medical records from 17 large health facilities in the
central and southern regions of Malawi, from January 2010 to December 2013. We included data from maternity
registers from all HIV-positive women, and randomly selected around every fourth woman with negative or
unknown HIV status. We used multivariable logistic regressions and cluster-based robust standard errors to examine
independent associations of patient- and facility characteristics with CS and ECS.
Results: We included 62,033 women in the analysis. The weighted percentage of women who had a spontaneous
vaginal delivery was 80.0% (CI 95% 79.5–80.4%); 2.4% (95% CI 2.3–2.6%) had a vacuum extraction; 2.3% (95% CI 2.2–
2.5%) had a vaginal breech delivery; 14.0% (95% CI 13.6–14.4%) had a CS while for 1.3% (95% CI 1.2–1.4%) the
mode of delivery was not recorded. Prevalence of CS without recorded medical or obstetric indication (ECS) was 5.
1%, (n = 3152). Presence of maternal and infant complications and older age were independently associated with
CS delivery. HIV-positive women were less likely to have ECS than HIV negative women (aOR 0.65; 95%-CI 0.57–0.
74). Among HIV-positive women, those on antiretrovirals (ARV’s) for ≥4 weeks prior to delivery were less likely to
have ECS than HIV-positive women who had not received ARVs during pregnancy (aOR 0.81; 95% CI 0.68–0.96).
Conclusions: The pattern of CS’s in Malawi is largely determined by maternal and infant complications. Positive HIV
status was negatively associated with CS delivery, possibly because health care workers were concerned about the
risk of occupational HIV transmission and the known increased risk of post-operative complications. Our results
leave open the possibility that CS is practiced to prevent MTCT given that ECS was more common among women
at high risk of MTCT due to no or short exposure to ARV’s.
* Correspondence: ltenthani@gmail.com
1Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi
2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tenthani et al. BMC Pregnancy and Childbirth  (2018) 18:95 
https://doi.org/10.1186/s12884-018-1722-4
Background
In 2014, an estimated 1.1 million people were living with
HIV in Malawi, including 130,000 children under fifteen
[1]. Mother-to-child transmission (MTCT) is the most
common cause of infection in children. Without inter-
vention, risk of MTCT is estimated to be 5–10% over
the course of pregnancy, 10–20% during labour, and 10–
20% during breastfeeding; overall 30–45% of infants
born to mothers with HIV will contract the virus [2].
With effective antiretroviral therapy (ART), the risk of
MTCT can be reduced to less than 5% [3].
In Malawi the total fertility rate is estimated to be be-
tween 4.4 and 5.7 children per woman. High ratios of
maternal mortality (460–680 per 100,000 live births) and
neonatal mortality (27 per 1000 live births) have been
recorded. The contraceptive prevalence rate varies be-
tween 44.4% (sexually active unmarried women) and 59.
2% (married women) [4]. Maternal mortality is believed
to be strongly impacted on by the HIV epidemic, with a
steep increase between 1992 and 2000 and a sharp de-
cline since the start of free ART provision in 2004 [4].
In this context, Malawi implemented a test and treat
policy (“Option B+”) to facilitate access to ART for all
HIV-infected pregnant and breastfeeding women [4]. The
policy was adopted by other low-income countries and is
now recommended by the World Health Organization [5].
Under Option B+, women are diagnosed with HIV during
routine testing in antenatal care and they initiate ART
within one week of diagnosis [4]. In 2011, Option B+ was
implemented as Malawi’s National PMTCT policy and the
ART coverage among pregnant women increased
strongly [6]. However, even with Option B+, a substan-
tial proportion of women are likely not to be fully
virologically suppressed when around 20% of pregnant
women are not tested for HIV [7]; almost 20% discon-
tinue treatment within the first months [8, 9]; and
about 30% adhere to ART inadequately during preg-
nancy, with young age and Option B+ indication for
ART as risk factors [10]. Overall, 9% of women who are
on ART during pregnancy do not achieve adequate
virological suppression at delivery [11].
Caesarean section (CS) can be used to reduce the risk of
intrapartum HIV transmission [12–14]. In high-income
countries CS is recommended for women with > 400 HIV
RNA copies/ml at the time of delivery [15, 16]. In resource
constrained settings like Malawi, elective caesarean
section (ECS; defined here as a CS without documented
obstetric or medical indication) is not a recommended
PMTCT strategy [17] as the increased risk of morbidity
and mortality that is associated with ECS is expected to
outweigh its HIV prevention benefits [18, 19]. In addition,
resources and capacity to perform CS are limited in low-
income countries like Malawi [19, 20]. Despite this, it is
possible that health care workers and pregnant women in
Malawi opt for an ECS in circumstances where MTCT
risk is known or believed to be high.
We describe the prevalence and pattern of indications
of CS among deliveries of HIV positive and HIV nega-
tive women in Malawi. We also explore our data for the
potential practice of using ECS for PMTCT.
Methods
Data sources
We entered routinely collected data from individual
medical records in 17 large health facilities in the central
and southern regions of Malawi, from January 2010 to
December 2013. The selected facilities were among 20
study facilities that participate in the Umoyo+ study (http://
aidsinfo.unaids.org/). Two of the 20 facilities were excluded
because no CS’s were done, another one because of missing
data. In the Malawi government health care system, obser-
vations from labour and delivery are recorded on labour
charts and summarized in a maternity register. These
standard monitoring and evaluation tools capture
demographic characteristics, obstetrical history, and
observations on the delivery and infant. Theatre registers
document detailed information about CS (i.e. indication,
duration, observations and outcome of the procedure). At
each health facility, we included data from maternity
registers from all HIV positive women and from a ran-
domly selected approximately one quarter of women with
negative or unknown HIV status. We describe the sampling
strategy in more detail in the Additional file 1: Appendix 1.
In case the indication for CS could not be determined from
the maternity register, we extracted relevant information
from labour charts and theatre registers.
Definitions
Health care workers classified the mode of delivery either as
CS or as vaginal delivery (including assisted vaginal deliveries
that use vacuum and forceps extraction). The main out-
comes of the study were CS and ECS. The delivery was de-
fined as CS when it was conducted through CS irrespective
of the reason for the procedure. A CS was classified as ECS
if it was conducted electively without documentation of an
obstetric or medical indication. In women with a previous
CS, the current CS was counted as ECS only if there was no
trial of vaginal delivery for the current delivery with no pre-
vious history of CS (if a previous CS was the indication for
the current CS, this will be reported according to local
guidelines). HIV status was positive if a woman was admitted
for labour and delivery with documentation of a positive
HIV test result or if she was on ART, or if she had a positive
test result obtained between the onset of labour and the
period immediately after delivery. A woman was classified as
HIV negative if she had a negative test result in that same
period or if she had a documented negative test result during
the current pregnancy. HIV unknown status was assigned if
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testing was not documented, if it was documented as not
done, or if test results were inconclusive or missing.
Statistical analysis
We provide patterns of indications for CS among HIV
positive, unknown and negative women using descriptive
statistics. To examine independent associations between CS
or ECS and patient and facility characteristics, we used
multivariable logistic regression analyses, with cluster-based
robust standard errors adjusting for clustering of patients
within facilities. We considered the following explanatory
variables: year of admission, maternal complications
(hemorrhage, obstructed/prolonged labour, pre-eclampsia,
maternal sepsis, ruptured uterus, others when unspecified,
unknown if nothing was recorded), infant complications
(prematurity, low birth weight, asphyxia, other if unspeci-
fied, unknown if nothing was recorded), HIV status (nega-
tive, positive, unknown), and ARV use during pregnancy
(no ARVs, ARVs for < 4 weeks, ARVs for≥4 weeks), number
of deliveries (0, 1, 2–3, > 3), singleton (yes/no), age category
(< 20, 20–24, 25–29, 30–34, > 34 years), facility ownership
(government or Christian Health Association (CHAM))
and location (urban or rural). We ran 4 models each to
examine predictors of CS and predictors of ECS. We
included all women in the first CS model; women with
unknown HIV status in the second, HIV negative women
in the third model and HIV positive women in the fourth.
In the four ECS models, we excluded women who had a
previous CS and failed trial of vaginal delivery and women
with a recorded maternal or infant complication (as these
women were not at risk of ECS) (Fig. 1). In all analyses HIV
negative women were weighted by the inverse of the prob-
ability that the observation was included because of the
sampling design. HIV positive women were assigned a
weight of 1 as data from all HIV positive women was ana-
lyzed (see sampling strategy description in Additional file 1:
Appendix 1). We therefore report weighted prevalence
rates throughout. All data were analyzed with STATA soft-
ware (Version 13.1, Stata Corporation, Texas USA.
Results
Characteristics of study participants
Out of 62,033 women included in the analysis 56,292 (90.
7%) had a known HIV status and 5741 (9.3%) had an un-
known HIV status. Among women with known HIV status
23,193 were HIV positive and 33,099 were HIV negative,
resulting in a weighted HIV prevalence of 9.7%. (95% CI 9.
3–10.1%). Characteristics of study participants stratified
Fig. 1 Flow chart showing the patients’ records included in the study and the specific model according to their HIV status and mode of delivery
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by HIV status are shown in Table 1. Their median age was
25 years (interquartile range [IQR] 20–30). Women had a
median of one delivery (IQR 1–3). The majority of women
(89.6%, 55,583) received care at government owned facil-
ities and 10.4% (6450) were managed in faith-based clinics.
About 76% of the women (47,215) attended clinics in rural
settings and 24% (14,818) were seen at urban clinics.
Maternal and infant complications
The proportion of women with maternal complications
was 12.5%(95% CI 12.1–12.9%). Maternal complications oc-
curred more frequently among HIV positive (15.2%; 95%
CI 14.8–15.7%) than among HIV negative women (11.5%;
95% CI 11.1–11.9%). Among women with unknown HIV
status the corresponding percentage was 16.2% (95% CI 15.
2–17.3%). The percentage of infants who had complications
was 14.5% (95% CI 14.1–14.8%). Infant complications were
more common among HIV exposed infants (25.1%, CI 24.
5–25.7%) than among infants born to mothers with nega-
tive (12.7%, CI 12.3–13.1%) or unknown HIV status (18.3%,
CI 17.2–19.5%). The distribution of specific maternal and
infant complications by HIV status is shown in Table 1.
Mode of delivery
The percentage of women who had a spontaneous vagi-
nal delivery was 80.0% (CI 95% 79.5–80.4%); 2.4% (95%
CI 2.3–2.6%) had vacuum extraction; 2.3% (95% CI 2.2–
2.5%) had a vaginal breech delivery; 14.0% (95% CI 13.6–
14.4%) had CS while for 1.3% (95% CI 1.2–1.4%) of the
women mode of delivery was not recorded.
Overall, prevalence of CS among women with unknown
HIV status was significantly higher than among deliveries
of HIV negative women, which in turn was significantly
higher than among deliveries in HIV positive women
(HIV unknown 16.2%, 95% CI 15.1–17.3%; HIV negative
13.8%, 95% CI 13.3–14.2%; HIV positive 12.1%, 95% CI
11.7–12.5%). The distribution of CS according to individ-
ual and facility-level characteristics stratified by HIV status
is shown in Table 2. Among women with a recorded com-
plication 64.4% (95% CI 63.9–64.9%) had a CS delivery
compared to 6.8% (95% CI 6.7–6.9%) in women without a
recorded complication. The prevalence of elective CS
without recorded medical or obstetric indication (ECS)
was 5.1% (95% CI 4.9–5.3%).
Associations of individual and facility level characteristics
with CS
HIV positive women were less likely to have CS compared
to HIV negative women (aOR 0.60; 95%-CI 0.51–0.71)
while those with unknown HIV status had similar odds of
CS as HIV negative women (aOR 1.01; 96% CI 0.84–1.20).
Table 3 shows the results from the multivariable logistic
regression analyses of variables associated with CS. Pres-
ence of maternal complications, infant complications and
older age were independently associated with CS delivery
in each of the three groups. Twin delivery and delivering
for the first time were associated with a higher probability
of CS in all groups. Year of admission was independently
associated with a lower odds of CS after 2010 only in HIV
negative women.
Associations of individual and facility level characteristics
with ECS
Results from the multivariable logistic regression analyses of
variables associated with ECS delivery among all women,
HIV positive women, those with unknown HIV status and
HIV negative women are presented in Table 4. HIV positive
women were less likely to have ECS compared to HIV nega-
tive women (aOR 0.65; 95%-CI 0.57–0.74). Among HIV
positive women, those who were on ARV’s for ≥4 weeks
prior to delivery were less likely to have ECS than HIV posi-
tive women who had not received ARVs during pregnancy.
Older age and delivery in an urban facility were associated
with higher odds of ECS in all groups. First deliveries and
non-singleton deliveries were independently associated with
an increased odds of ECS in all groups except in women
with HIV unknown status. Delivery in 2010, was independ-
ently associated with ECS, except in HIV positive women.
Discussion
We found that the prevalence of CS in deliveries in 17 large
health facilities in Malawi was 14.0% and was higher among
deliveries of HIV negative women compared to HIV posi-
tive women. The 14% CS prevalence found in our study is
almost three times higher than the 5% last reported in the
2010 nationally representative study [21, 22] and the 6.2%
reported in a multinational study in sub-Saharan Africa
[23]. However this can be explained by our exclusion of
deliveries taking place in primary health facilities where CS
services are not offered.
CS delivery was strongly associated with presence of ma-
ternal or infant complications. As expected, maternal and
infant complications were more common among HIV posi-
tive women than HIV negative women, while those with
unknown HIV status had similar frequency of complica-
tions to HIV positive women (possibly due to undiagnosed
HIV among those with unknown status). We also found
that among HIV positive women the chance of ECS was
higher in those who had received less than 4 weeks or no
exposure to ARVs during pregnancy. As in other studies
the adjusted odds of a CS delivery increased with age and
almost doubled among HIV positive women aged above
29 years compared to those below 20 years [24–27].
Our data suggest that patterns of CS in Malawi are
also influenced by other factors than maternal and fetal
obstetric conditions. The lower frequency of CS among
HIV positive women in spite of their higher maternal
and infant complication rates could be explained by
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Table 1 Characteristics of study participants by HIV status
Item All women
(n = 62,033)
Women with unknown
HIV status (n = 5741)
HIV negative women
(n = 33,099)
HIV positive women
(n = 23,193)
Total Weighted % Total Weighted % Total Weighted % Total Weighted %
Year of admission 2010 10,526 20.8 675 18.4 4272 20.9 5579 24.1
2011 16,216 30.9 1647 38.2 7056 29.4 7513 32.4
`2012 16,749 22.6 1888 23.6 9889 22.5 4972 21.4
2013 18,542 25.8 1531 19.9 11,882 27.2 5129 22.1
Maternal complication None 52,992 86.8 4674 82.4 28,932 88.0 19,386 83.6
Hemorrhage 1566 2.0 173 2.9 621 1.7 772 3.3
OPL 2899 4.3 312 5.0 1413 4.7 1175 5.1
Preeclampsia 511 0.8 78 1.2 260 0.7 173 0.7
Sepsis 101 0.1 13 0.3 21 0.1 67 0.3
RU 161 0.2 28 0.5 68 0.2 65 0.3
Unspecified 3275 5.0 386 6.4 1610 4.7 1278 5.5
Unknown 528 0.7 77 1.4 174 0.5 277 1.2
Infant complication None 51,017 85.8 4691 82.1 28,892 87.6 17,435 75.2
Prematurity 2609 3.6 281 4.7 1163 3.3 1156 5.0
LBW 2166 3.0 261 4.8 844 2.5 1073 4.6
Asphyxia 2140 3.4 246 3.9 1158 3.3 732 3.2
Unspecified 1683 2.6 197 3.3 811 2.4 675 2.9
Unknown 2418 1.6 65 1.2 231 0.8 2122 9.1
No of previous deliveries 0 14,446 29.1 1738 30.6 10,125 30.8 2583 11.1
1 12,554 21.2 1138 19.9 7314 21.8 4102 17.7
2–3 19,780 28.0 1505 26.2 8856 26.9 9419 40.6
> 3 14,554 20.5 1180 20.4 6523 19.6 6851 29.5
Unknown 699 1.2 180 2.9 281 0.9 238 1.0
Age in years < 20 11,191 23.0 1428 26.3 8217 24.4 1546 6.7
20–24 17,485 31.0 1738 30.5 10,491 32.0 5256 22.7
25–29 14,003 20.0 1035 17.1 6374 19.5 6595 28.4
30–34 10,960 13.9 740 12.5 4389 12.9 58,31 25.1
> 34 7288 10.2 583 9.8 3094 9.6 3610 15.6
Unknown 1106 1.9 217 4.0 534 1.6 355 1.5
Singleton Yes 59,862 96.6 5519 96.1 32,068 96.7 22,274 96.0
No 2171 3.4 222 3.9 1031 3.3 919 4.0
ARVs during pregnancy None, HIV+ 11,938 4.3 N/A 11,938 51.5
<4wks 2716 1.0 2716 11.7
≥4wks 8539 3.1 8539 36.8
None, HIV- 38,840 91.6 N/A
Facility ownership Government 55,583 89.6 5476 95.3 29,447 88.1 20,660 89.1
CHAM 6450 10.4 265 4.7 3652 11.9 2533 10.9
Facility location Rural 47,215 80.4 4936 86.2 26,660 80.8 15,619 67.3
Urban 14,818 19.6 805 13.8 6439 19.2 7574 32.7
aOR adjusted odds ratio, OPL obstructed/prolonged labor, RU Ruptured Uterus, LBW Low Birth Weight, ARVs antiretrovirals, CHAM Christian Health Association
of Malawi
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Table 2 Proportion of women who delivered through C-section according to baseline characteristics
Item All Women
(n = 62,033)
Women with unknown
HIV status (n = 5741)
HIV negative women
n = 33,099)
HIV positive women
n = 23,193
Year of admission 2010 15.2 (14.2–16.3) 17.2 (14.3–20.7) 15.1 (13.9–16.4) 13.7 (12.8–14.6)
2011 13.7 (12.9–14.5) 13.4 (11.7–15.4) 13.8 (12.9–14.9) 13.3 (12.5–14.1)
2012 13.4 (12.8–13.9) 18.2 (16.6–20.1) 12.8 (12.2–13.5) 9.6 (8.8–10.5)
2013 13.8 (13.3–14.4) 18.1 (16.2–20.1) 13.5 (12.9–14.1) 11.0 (10.2–11.9)
Maternal complication None 6.6 (6.3–6.9) 6.3 (6.1–6.6) 6.8 (6.6–6.9) 5.1 (4.8–5.4)
Hemorrhage 29.5 (26.5–32.8) 34.7 (32.0–37.6) 30.2 (28.7–31.7) 19.0 (16.4–22.0)
OPL 68.2 (65.8–70.4) 68.0 (65.9–70.0) 69.2 (68.2–70.1) 60.9 (58.0–63.6)
Preeclampsia 60.2 (55.0–65.2) 64.8 (60.4–69.1) 61.2 (58.7–63.6) 39.3 (32.3–46.8)
Sepsis 16.5 (7.3–33.3) 5.1 (2.1–11.5) 30.7 (23.4–39.2) 6.0 (2.2–14.9)
RU 87.4 (78.5–93.0) 84.7 (78.6–89.4) 90.7 (87.6–93.1) 72.3 (60.2–81.9)
Unspecified 75.7 (73.5–77.8) 77.0 (75.3–78.6) 77.2 (76.3–78.0) 61.4 (58.7–64.1)
Unknown 33.0 (27.6–38.8) 31.9 (28.1–36.1) 36.6 (33.8–39.4) 20.6 (16.2–25.8)
Infant complication None 12.4 (12.0–12.8) 13.9 (13.5–14.3) 12.3 (12.1–12.4) 11.2 (10.7–11.7)
Prematurity 17.0 (15.1–19.1) 21.7 (19.9–23.7) 16.1 (15.3–17.0) 15.2 (13.3–17.4)
LBW 20.8 (18.4–23.4) 16.1 (14.5–17.8) 23.0 (21.9–24.1) 18.0 (15.8–20.4)
Asphyxia 29.2 (26.7–31.8) 40.0 (37.5–42.5) 26.8 (25.8–27.8) 30.2 (27.0–33.6)
Unspecified 32.4 (29.5–35.5) 36.8 (34.2–39.5) 31.8 (30.6–33.1) 29.2 (25.9–32.7)
Unknown 15.7 (12.9–19.1) 15.5 (12.5–19.0) 31.2 (29.1–33.4) 2.7 (2.1–3.5)
No of previous deliveries 0 16.3 (15.5–17.1) 16.2 (15.5–16.9) 16.2 (16.0–16.5) 18.7 (17.3–20.3)
1 14.2 (13.3–15.0) 15.9 (15.1–16.8) 14.0 (13.7–14.3) 12.6 (11.6–13.6)
2–3 13.3 (12.6–14.0) 17.8 (17.0–18.5) 12.7 (12.5–13.0) 11.6 (11.0–12.3)
> 3 11.2 (10.5–12.1) 13.8 (13.0–14.6) 11.0 (10.7–11.3) 9.9 (9.2–10.6)
Unknown 17.4 (14.1–21.3) 20.2 (18.0–22.7) 16.2 (14.6–17.9) 14.3 (10.4–19.3)
Age in years < 20 14.3 (13.5–15.1) 13.3 (12.6–14.0) 14.5 (14.2–14.8) 13.6 (12.0–15.5)
20–24 14.6 (13.9–15.4) 18.5 (17.8–19.3) 14.2 (13.9–14.4) 12.3 (11.4–13.2)
25–29 14.6 (13.8–15.5) 18.7 (17.8–19.6) 14.4 (14.1–14.7) 11.8 (11.1–12.6)
30–34 12.1 (11.2–13.0) 13.7 (12.8–14.7) 11.8 (11.4–12.2) 11.9 (11.1–12.8)
> 34 12.6 (11.5–13.8) 15.3 (14.2–16.5) 12.2 (11.8–12.7) 11.9 (10.9–13.0)
Unknown 13.6 (11.1–16.4) 15.3 (13.6–17.3) 13.0 (11.9–14.1) 12.4 (9.3–16.3)
Singleton Yes 13.7 (13.4–14.1) 16.0 (15.7–16.4) 13.6 (13.4–13.7) 11.7 (11.3–12.2)
No 20.4 (17.9–23.0) 19.7 (17.8–21.8) 20.4 (19.5–21.4) 20.8 (18.2–23.4)
ARVs during pregnancy None 11.7 (11.1–12.3) N/A 11.7 (11.1–12.3)
<4wks 12.4 (11.3–13.7) 12.4 (11.3–13.7)
≥4wks 12.5 (11.9–13.2) 12.5 (11.9–13.3)
HIV- & Unknown 14.1 (13.7–14.6) N/A
Facility ownership Government 13.8 (13.4–14.2) 16.2 (15.8–16.5) 13.5 (13.4–13.7) 12.2 (11.8–12.7)
CHAM 15.3 (14.1–16.7) 16.6 (15.0–18.4) 15.7 (15.2–16.1) 11.3 (10.1–12.5)
Facility location Rural 13.6 (13.4–13.7) 16.0 (15.6–16.4) 13.3 (13.1–13.4) 11.4 (10.9–11.9)
Urban 15.7 (15.4–16.0) 17.3 (16.3–18.3) 15.9 (15.5–16.2) 13.6 (12.9–14.4)
Totals 14.0 (13.6–14.4) 16.2 (15.1–17.3) 13.8 (13.3–14.2) 12.1 (9.1–15.1)
OPL obstructed/prolonged labor, RU Ruptured Uterus, CHAM Christian Health Association of Malawi, LBW Low Birth Weight, aOR adjusted odds ratio,
ARVs antiretrovirals
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strict CS indication setting by health care workers in
recognition of the increased post-operative morbidity
and mortality [28–30]. Clinicians may also be reluctant
to perform ECS in HIV infected women due to a per-
ceived risk of occupational HIV transmission [31].
Stigma and discrimination related to HIV infection may
also play a role on health care workers’ decision making
[32]. On the other hand, we observed that among HIV
positive women the prevalence of CS and ECS was
higher in those who had no or less than 4 weeks of ex-
posure to ARVs (i.e. were at high MTCT risk) than in
women with longer ARV drug usage in pregnancy. This
suggests that high MTCT risk is being considered as an
indication for CS in Malawian clinical practice.
Table 3 Individual and facility-level factors associated with C-Section among women delivering in 17 large health facilities in Malawi
Item aOR (95% CI)
All Women
(55,443)
p aOR (95% CI) Women
with Unknown HIV
status (n = 5302)
P aOR (95% CI)
HIV- Women
(n = 31,978)
p aOR (95% CI)
HIV+ Women
(n= 20,436)
P
Year of
admission
2010 1 0.07 1 0.09 1 0.02 1 0.06
2011 0.71 (0.50–1.01) 0.58 (0.37–0.91) 0.71 (0.50–1.00) 1.00 (0.73–1.38)
2012 0.65 (0.45–0.93) 0.71 (0.42–1.19) 0.61 (0.43–0.88) 0.83 (0.56–1.22)
2013 0.67 (0.49–0.92) 0.67 (0.43–1.07) 0.65 (0.48–0.87) 1.04 (0.73–1.49)
Maternal
Obstetric
Complication
None 1 < 0.01 1 < 0.01 1 < 0.01 1 < 0.01
Hemorrhage 5.85 (3.12–10.97) 7.02 (4.26–11.58) 5.80 (3.03–11.12) 4.25 (1.72–10.47)
OPL 32.23 (17.15–60.57) 29.43 (17.75–48.80) 33.61 (16.99–66.47) 29.88 (11.89–75.13)
Preeclampsia 21.76 (10.32–45.86) 27.18 (14.18–52.09) 22.14 (9.83–49.88) 11.23 (4.56–27.68)
Sepsis 4.25 (1.30–13.85) 1.35 (0.14–13.18) 8.13 (1.57–42.16) 1.20 (0.36–4.02)
RU 160.25 (75.41–340.51) 141.95 (34.98–576.08) 186.48 (66.45–523.27) 94.91 (43.33–207.89)
Others 52.85 (31.25–89.39) 51.75 (35.26–75.97) 55.-81 (33.24–93.69) 38.01 (15.13–95.52)
Infant
Complication
None 1 0.01 1 < 0.01 1 < 0.01 1 < 0.01
Prematurity 0.99 (0.77–1.29) 1.12 (0.61–2.05) 0.95 (0.61–1.46) 1.11 (0.87–1.42)
LBW 1.40 (1.07–1.83) 0.77 (0.38–1.58) 1.75 (1.28–2.39) 1.09 (0.77–1.53)
Asphyxia 1.86 (1.29–2.67) 3.02 (1.83–4.96) 1.65 (1.08–2.53) 1.92 (1.33–2.76)
Others 1.59 (1.15–2.19) 2.20 (1.07–4.52) 1.53 (1.10–2.11) 1.14 (0.73–1.78)
No of
previous
deliveries
0 1 < 0.01 1 0.31 1 < 0.01 1 < 0.01
1 0.83 (0.74–0.93) 0.84 (0.63–1.12) 0.84 (0.74–0.95) 0.61 (0.49–0.76)
2–3 0.68 (0.56–0.83) 0.79 (0.55–1.13) 0.68 (0.55–0.84) 0.50 (0.40–0.62)
> 3 0.52 (0.41–0.66) 0.72 (0.50–1.05) 0.51 (0.39–0.67) 0.35 (0.26–0.45)
Age (years) < 20 1 < 0.01 1 0.02 1 0.01 1 < 0.01
20–24 1.28 (1.12–1.47) 1.75 (1.25–2.44) 1.20 (1.04–1.39) 1.37 (1.12–1.67)
25–29 1.56 (1.27–1.93) 1.96 (1.23–3.11) 1.49 (1.16–1.92) 1.72 (1.34–2.21)
30–34 1.44 (1.15–1.81) 1.66 (0.99–2.78) 1.35 (1.03–1.78) 1.98 (1.50–2.61)
> 34 1.63 (1.34–1.99) 1.62 (1.00–2.64) 1.57 (1.21–2.03) 2.24 (1.75–2.85)
Singletons Yes 1 < 0.01 1 0.35 1 0.03 1 0.04
No 1.49 (1.10–2.03) 1.31 (0.74–2.33) 1.51 (1.05–2.16) 1.58 (1.03–2.43)
ARVs during
Pregnancy
None N/A N/A N/A 1 0.83
<4wks N/A N/A N/A 0.98 (0.72–1.32)
≥4wks N/A N/A N/A 0.96 (0.81–1.12)
Facility
Ownership
Govt. 1 0.90 1 0.57 1 0.36 1 0.77
CHAM 1.42 (0.65–3.13) 1.27 (0.55–2.94) 1.48 (0.64–3.41) 1.09 (0.62–1.90)
Facility
Location
Rural 1 0.27 1 0.26 1 0.13 1 0.23
Urban 1.39 (0.91–2.12) 1.19 (0.88–1.62) 1.47 (0.89–2.41) 1.16 (0.91–1.46)
OPL obstructed/prolonged labor, RU Ruptured Uterus, CHAM Christian Health Association of Malawi, LBW Low Birth Weight, aOR adjusted odds ratio,
ARVs antiretrovirals
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We are not aware of other publications that assessed
why women or health care workers opt for an ECS in sub-
Saharan Africa. Most of the recent publications focused
on the effect of early ART and Option B+ on PMTCT [33,
34]. A recent systematic review [35] assessed the risks and
benefits of ECS in women with HIV. Of 36 studies in-
cluded, only 3 were done in sub-Saharan Africa. Two of
these studies described risk factors for MTCT [36, 37].
Unger et al. analyzed the use of CS over time, and assessed
postpartum morbidity and mortality; but they did not dis-
cuss why the use of CS increased over time [38].
Our data showed that ECS was more frequent among
women who delivered in urban than rural facilities. Sev-
eral studies observed a higher prevalence of CS in urban
settings and this was mostly driven by demands from
mothers or by provider preferences [20, 32, 39] although
it is also possible that the difference reflects the larger
availability of surgery facilities in urban areas. The rea-
son why this difference was only observed in analyses of
ECS and not of all CS, may be due to the fact that de-
mands from mothers and provider preferences are not
formally accepted indications for CS in guidelines, thus
are not reported in registers and delivery charts or due
to the fact that knowledge about the potential use of CS
for MTCT is higher in urban areas.
Some studies have shown a declining trend in CS upon
wider availability of ARVs [40]. We also saw a reduction
in CS and ECS deliveries after 2010, but remarkably not
in HIV positive women, suggesting that other factors
than increased ART coverage determined this [6].
The study has several strengths and limitations. It is
based on a large dataset and includes health facilities in
different regions in Malawi. Generalization of the results of
this study needs to be considered with care because the
data were from large health facilities only. Another limita-
tion is that we used routinely collected medical records
which may have affected data quality. The proportion of
missing data from explanatory variables was below 5%, ex-
cept for infant complications (Table 1) and we believe it is
unlikely that data were systematically missing for particular
groups. In our study, the HIV status variable could be
determined by HIV test results that became available before
the onset of labour and immediately after delivery. In the
latter case HIV status could not have impacted on a CS/
ECS decision. Because all HIV testing in Malawi is with
rapid point-of-care tests that provide a result within
Table 4 Individual and facility-level factors associated with Elective Caesarean Section
Item aOR (95% CI)
All Women
(55,443)
p aOR (95% CI) Women with
Unknown HIV status
(n = 4764)
p aOR (95% CI)
HIV- Women
(n = 29,747)
p aOR (95% CI)
HIV+ Women
(n = 20,932)
p
Year of Admission 2010 1 0.03 1 0.01 1 0.02 1 < 0.09
2011 0.63 (0.42–0.94) 0.47 (0.29–0.76) 0.64 (0.43–0.96) 0.84 (0.55–1.30)
2012 0.55 (0.34–0.88) 0.61 (0.31–1.22) 0.53 (0.33–0.86) 0.55 (0.28–1.06)
2013 0.53 (0.35–0.83) 0.40 (0.21–0.78) 0.54 (0.36–0.82) 0.68 (0.39–1.19)
No of deliveries 0 1 < 0.01 1 0.11 1 < 0.01 1 < 0.01
1 0.76 (0.66–0.87) 0.74 (0.57–0.96) 0.77 (0.66–0.90) 0.59 (0.46–0.75)
2–3 0.65 (0.51–0.82) 0.68 (0.42–1.11) 0.65 (0.51–0.83) 0.49 (0.38–0.63)
> 3 0.46 (0.34–0.63) 0.68 (0.40–1.16) 0.45 (0.31–0.65) 0.31 (0.22–0.43)
Age (years) < 20 1 < 0.01 1 < 0.01 1 < 0.01 1 < 0.01
20–24 1.38 (1.18–1.61) 2.07 (1.42–3.03) 1.29 (1.09–1.53) 1.46 (1.12–1.91)
25–29 1.68 (1.35–2.09) 2.11 (1.21–3.67) 1.60 (1.25–2.06) 1.86 (1.33–2.60)
30–34 1.46 (1.10–1.92) 1.44 (0.81–2.54) 1.37 (1.00–1.88) 2.19 (1.40–3.43)
> 34 1.68 (1.24–2.27) 1.93 (1.07–3.50) 1.58 (1.08–2.32) 2.26 (1.57–3.27)
Singletons Yes 1 < 0.01 1 0.13 1 < 0.01 1 < 0.01
No 1.98 (1.55–2.54) 1.48 (0.90–2.46) 2.06 (1.54–2.77) 2.27 (1.51–3.41)
ARVs during Pregnancy None N/A N/A N/A 1 0.04
<4wks N/A N/A N/A 0.96 (0.73–1.27)
≥4wks N/A N/A N/A 0.81 (0.68–0.96)
Facility Ownership Government 1 0.69 1 0.47 1 0.72 1 0.80
CHAM 1.63 (0.69–3.83 1.19 (0.74–1.91) 1.75 (0.72–4.27) 1.08 (0.59–1.99)
Facility Location Rural 1 0.03 1 0.01 1 0.03 1 < 0.01
Urban 1.95 (1.06–3.56) 1.52 (1.17–1.98) 2.02 (1.05–3.86) 2.15 (1.27–3.64)
CHAM Christian Health Association of Malawi, aOR adjusted odds ratio, ARVs antiretrovirals
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30 min, most results would have been obtained before de-
livery, but we do not have data to document this. Further,
we assumed that CS was elective when no obstetric indica-
tion was recorded, while there could simply be missing ob-
stetric data. We limited this as much as possible by
complimenting maternity register data with information
from labour charts and theatre registers.
We did not have data on ART adherence or treatment
interruptions. Health care workers may have considered
CS more frequently in patients with poorer adherence
because they know that suboptimal adherence impairs
the preventive effect of PMTCT.
Conclusions
We have shown that patterns of CS in Malawi are largely
determined by maternal and infant complications. Positive
HIV status was inversely associated with CS delivery, pos-
sibly related to health care workers’ perceived risk of occu-
pational HIV transmission and the recognition of the
known higher rate of post-operative complications. Our re-
sults leave open the possibility that CS is practiced as a
means of PMTCT in Malawi as we found that ECS was sig-
nificantly more common among women with a high risk of
MTCT due to no or short exposure to ARVs in pregnancy
in a setting with limited access to viral load testing. Further
studies are needed to confirm our findings, including
surveys among providers of CS services and qualitative re-
search involving patients and practitioners about factors re-
lated ECS decisions including stigma and wealth.
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